Hallwang Clinic GmbH

What Hallwang Clinic GmbH does

Hallwang Clinic GmbH is a privately held, state-regulated specialty oncology clinic located in the Black Forest region of Dornstetten/Hallwangen, Germany, operating on a pure self-pay basis with no contracts with statutory or private health insurers. The clinic serves an international catchment of patients with advanced, metastatic, or therapy-resistant cancers who have exhausted standard-of-care options in their home countries, drawing case referrals from Australia, the United Kingdom, France, Macedonia, Latvia, Canada, Ukraine, and the United States alongside its German home market. The owner and Managing Director is Albert Schmierer, with medical direction provided by oncologist Dr. Jens Nolting; the clinic is explicitly described as a small private clinic with 24/7 medical coverage.

The core service is precision-based personalized cancer therapy, built on a comprehensive molecular diagnostics stack that includes next-generation sequencing, liquid biopsy with ctDNA assessment, genetic tumor analysis, multiplex immunohistochemistry with spatial profiling, and whole-exome sequencing. These diagnostics feed three treatment pillars: immunotherapy (immune checkpoint inhibitors, antibody-drug conjugates, dendritic cell therapy, personalized peptide vaccines, combination strategies), molecular-targeted therapies (multikinase inhibitors, PARP inhibitors, BRAF/MEK inhibitors, HER2-targeted agents), and interventional cancer therapy (CyberKnife, HIFU, TACE, chemotherapy). Supportive integrative medicine — including hyperthermia, hyperbaric oxygen therapy, orthomolecular medicine, ozone therapy, and personalized infusion programs — is positioned as an adjunct to improve tolerance and quality of life. AI is integrated into diagnostics via multi-modal models combining genomic, imaging, clinical, and histopathologic data, and the clinic operates an AI Knowledge Base / AI Grounding Hub for AI-engine discoverability.

The business model is direct-to-patient professional services: free initial telephone consultation with the oncology team, individual case review, personalized treatment plan and cost estimate, advance payment required, and treatment delivered on-site in Germany. Go-to-market relies on organic social media across five platforms, content marketing, prominently featured patient testimonials organized by cancer type, and a co-operative network of university hospitals and institutes. Revenue is entirely self-pay, with no insurance, charity, or foundation involvement, and no publicly disclosed financial metrics.

Name

Hallwang Clinic GmbH

Legal name

Hallwang Clinic GmbH

Website

https://hallwang-clinic.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Hallwang Clinic GmbH is a privately held German specialty oncology clinic in the Black Forest offering precision-based personalized cancer therapy — including NGS-guided immunotherapy, molecular-targeted therapy, and interventional oncology — to international self-pay patients with advanced or therapy-resistant cancers.

Ownership category

akta.pro rank

Product category

Private Oncology Clinic

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Thoracic (Lung) Oncology (HLAKAFAL)

Keywords

• Precision oncology services
• Personalized cancer therapy
• Immunotherapy treatments
• Molecular diagnostics
• Integrative oncology care

Headquarters

HQ city

Dornstetten / Hallwangen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Private-Pay Oncology Treatment: Pure self-pay model with no contracts to statutory German health insurance or private health insurance companies. No support from charities or foundations. Treatment costs are settled directly by patients. Individual case review with personalized cost estimate provided prior to admission with advance payment required.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Core offering

Hallwang Clinic GmbH is a private-pay oncology clinic delivering individualized, precision-based cancer therapy to international patients. Its core offering combines comprehensive molecular diagnostics (NGS, liquid biopsy, ctDNA assessment, multiplex immunohistochemistry) with advanced treatment modalities including immunotherapy, molecular-targeted therapy, interventional procedures (CyberKnife, HIFU, TACE) and supportive integrative medicine, all delivered under German regulatory medical-freedom provisions to patients with advanced, metastatic or therapy-resistant cancers.

Product overview

Hallwang Clinic GmbH is a state-regulated private oncology clinic in Germany offering a unified precision oncology service portfolio centered on individualized, evidence-based cancer therapy. The core offering is Precision-Based Personalized Cancer Therapy, supported by three primary treatment pillars: Immunotherapy (checkpoint inhibitors, antibody-drug conjugates, dendritic cell therapies, peptide vaccines), Cancer Therapy (interventional procedures including CyberKnife, HIFU, TACE, and chemotherapy), and Molecular-Targeted Therapies. Precision Diagnostics — including liquid biopsy, NGS, genetic profiling, and whole-exome sequencing — informs all treatment decisions. Integrative Medicine provides supportive complementary care (hyperthermia, orthomolecular medicine, physiotherapy, nutritional therapy). An AI Knowledge Base (AI Grounding Hub) serves as a semantic reference for AI systems. The clinic treats all stages of hemato-oncological diseases and specializes in advanced/metastatic (Stage IV) and therapy-resistant cases, operating on a private-pay model without insurance contracts.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision-Based Personalized Cancer Therapy Individualized, precision-based oncology treatment tailored to each patient's molecular tumor profile, immune status and clinical context, combining molecular diagnostics with targeted immunotherapy, molecular-targeted therapy and combination treatment strategies. Intended for international private-pay cancer patients, with a particular focus on advanced, metastatic or therapy-resistant disease.
• Immunotherapy A suite of immunotherapies offered for numerous tumor diseases, including immune checkpoint inhibitors, personalized peptide vaccines, antibody-based therapies, antibody-drug conjugates (ADCs), dendritic cell therapies and combination immunotherapeutic approaches. Intended for international private-pay cancer patients.
• Cancer Therapy Surgical and interventional procedures aimed at eliminating tumors, including CyberKnife, HIFU, nuclear medicine, transarterial chemoembolization (TACE) and standard chemotherapy. Intended for international private-pay cancer patients.
• Molecular-Targeted Therapies Targeted drug treatments directed at specific molecular alterations in tumors, including multikinase inhibitors (VEGFR, MET, RET), PARP inhibitors, BRAF/MEK inhibitors and HER2-targeted agents, selected on the basis of individual tumor profiling. Intended for international private-pay cancer patients.
• Stage 4 Cancer Therapies Specialized treatment protocols for advanced and metastatic (Stage IV) cancer and complex therapy-resistant cases, using precision diagnostics and individualized therapeutic strategies beyond standard of care. Intended for international private-pay patients who have exhausted standard treatment options.
• Precision Diagnostics Comprehensive diagnostic services including genetic tumor analysis, molecular tumor profiling, liquid biopsy (circulating tumor DNA / ctDNA), next-generation sequencing (NGS), multiplex immunohistochemistry and spatial profiling, and whole-exome sequencing, used to guide targeted therapy selection. Intended for international private-pay cancer patients.

Quantifiable outcome

• Patient testimonials report complete remission in cases of advanced NSCLC with brain metastases, Stage IV ovarian cancer, and other metastatic cancers
• +2 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Asklepios Kliniken GmbH: One of Germany's largest private hospital groups, operating multiple specialty hospitals including oncology centers with private-pay options; overlaps with Hallwang on the private German oncology care segment at much greater scale.
• Helios Kliniken GmbH: Major German private hospital operator (part of Fresenius) running numerous specialty hospitals across Germany, including oncology services; competes for both domestic and international private-pay oncology patients.
• Charité Private Ward (Charité Universitätsmedizin Berlin): Germany's largest university hospital operates a private ward for international and self-paying patients seeking advanced oncology, including precision medicine and clinical-trial-adjacent therapies, competing with Hallwang for affluent international patients.

Others

• Guardant Health: Specialist in liquid biopsy and ctDNA-based testing for advanced cancer, with a strong international footprint; comparable to Hallwang's use of liquid biopsy for treatment selection and monitoring.
• Tempus AI: US-based precision medicine company combining multi-modal data (genomic, imaging, clinical) with AI for oncology decision support; comparable to Hallwang's AI-powered diagnostic integration approach at much larger scale.
• Foundation Medicine (Roche): US-based leader in comprehensive genomic profiling (NGS, liquid biopsy) used to guide targeted therapy selection; comparable to Hallwang's precision diagnostics arm, though operating as a B2B diagnostic lab rather than a treatment provider.
• Hallwang Clinic is a real, identifiable company; listed above are its closest comparables in the German private oncology clinic space. Other niche German private specialty clinics (e.g., Klinik Marinus, Hufeland Klinik) operate in adjacent but narrower indications and were not included due to limited oncology specificity.

Emerging players

• Burjeel Holdings: UAE-based private hospital group building a regional hub for complex and international cancer care, including advanced therapies; competes with Hallwang for medical-tourism oncology patients from the Middle East, Africa and South Asia.
• Clemenceau Medical Center (affiliated with Johns Hopkins): Dubai/Lebanon-based private hospital network positioning itself as a regional destination for advanced cancer care, including precision oncology, attracting medical-tourism patients from the MENA region.

Direct peers

• Medias Klinikum GmbH & Co. KG: German private oncology clinic offering specialized, individualized cancer treatment with a focus on innovative therapies, including immunotherapy and personalized treatment protocols, for self-paying patients — a near-direct comparison to Hallwang's business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/HallwangHpoc
• YouTubeyoutube.com/channel/UCbqUjjx_2RXmMkIRxSj2BRQ
• Facebookfacebook.com/HallwangClinic
• LinkedInlinkedin.com/company/hallwang-clinic
• Instagraminstagram.com/hallwang_clinic

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hallwang Clinic GmbH